REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Strength Builder Stack

Fat Lossadvanced
0
Peptides

2

Avg Daily mcg

10,300

Level

advanced

Added

Apr 24, 2026

Overview

Metabolic health stack for improving insulin sensitivity and energy utilization.

Dosing Protocol

MOTS-c

2x/week· subcutaneous

10,000 mcg

per dose

AOD-9604

Every day· subcutaneous

300 mcg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.